Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain. (20th January 2022)

• Record Type: Journal Article
• Authors: Miranda, Hugo F.; Noriega, Viviana; Sierralta, Fernando; Sotomayor‐Zárate, Ramón; Prieto, Juan Carlos
• Is Part Of: Fundamental & clinical pharmacology. Volume 36:Number 3(2022)
• Page Start: 494
• Page End: 500
• Publication Date: 2022-01-20
• Subjects: meloxicam -- paracetamol -- phasic pain -- risperidone -- tonic pain; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/fcp.12754
• Languages: English
• ISSNs: 0767-3981

Abstract

Abstract: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the best therapeutic options to treat pain. Their use in combination with other drugs may broaden their applicability in analgesia if their ceiling and adverse effects are reduced. The aim of this study was to evaluate the pharmacological interaction of two NSAIDs, paracetamol and meloxicam, with the antipsychotic drug risperidone in mice, in several experimental tests of nociceptive and inflammatory pain. Antinociception was assessed by dose–response curves to paracetamol and meloxicam before and after the i.p. administration of 0.5 mg/kg of risperidone. Results are presented as means ± SEM and differences were calculated by one‐way ANOVA followed by Tukey's post‐test. Paracetamol and meloxicam produced a dose‐related antinociceptive effect with diverse potencies. Risperidone increased the analgesia mediated by paracetamol and meloxicam only in the tonic tests that detected inflammatory pain. This suggests that COX inhibition is only a partial explanation of the increased analgesic potency of paracetamol and meloxicam since the effects of NSAIDs in the CNS are mediated by multiple mechanisms. These results indicate that the combination of risperidone with paracetamol or meloxicam could be a new and effective alternative for the management of inflammatory pain.